ArticleScientific reports2025
The open-source multi-wavelength non-invasive blood glucose sensing system.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Diabetes treatment requires reliable blood glucose monitoring to allow for appropriate adjustments and interventions. The conventional finger-prick test is associated with significant discomfort and poor compliance, highlighting the critical need for non-invasive, user-friendly solutions. This study proposes and validates an open-source, multi-wavelength spectroscopy system that combines visible (660 nm) and near-infrared (940 nm) wavelengths through six distinct transmission and reflection strategies. The system was validated through a rigorous three-phase process. Phase I established a preliminary regression model against a commercial meter using 500 controlled samples ([Formula: see text] up to 0.8832). Phase II expanded this validation in 96 healthy volunteers, confirming high clinical acceptability (over 95% in Zone A, Clarke Error Grid) and a mean absolute error of 8.438 mg/dL relative to the commercial device. Critically, Phase III performed a definitive clinical validation, comparing our system and the commercial meter against the venous plasma glucose (VPG) gold standard. This analysis definitively established the clinical failure of all reflection-based strategies (resulting in Zone D errors), while confirming 100% clinical safety (Zones A/B) for all transmission modes. Notably, our multi-wavelength transmission (MT) strategy achieved 100% Zone A accuracy and demonstrated superior analytical precision (tighter ISO 15197:2015 compliance) than the ISO-compliant commercial benchmark when both were compared to the VPG. This work validates a transparent, open-source platform as a clinically reliable and accurate non-invasive alternative for intermittent glucose monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.